Innovation Pharmaceuticals Inc (IPIX)

[Chronic]

Thank you BooDog. You made my point. I was talking specifically about the "Weekly" regimen subgroup.

From IP's own press release:

Incidence of severe OM in Modified Intent to Treat (mITT) Population: Brilacidin 42.9%, Placebo 60.0%.

Now if you subtract the numbers from the "21 day" regimen, you will see that for the "weekly" regimen subgroup, the Placebo outperformed B-OM.

Also if you remember interim results were released which were fantastic, yet final results were only 42.9 to 60. Ok but not great. Again, shows results between interim and final were about even with placebo.

These are the facts based on IPIX's own press releases. Feel free to calculate for yourself.